Clinical Study of Previously Untreated Patients With Malignant Melanoma
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
Previously untreated patients with malignant melanoma receive a new chemotherapy drug
currently under development. CP-4055 is given intravenously on days 1-5 every four weeks
until complete response or disease progression.